Nanobiotix Newswire

Nanobiotix Newswire

Comprehensive Real-Time News Feed for Nanobiotix.

Results 1 - 20 of 36 in Nanobiotix

  1. Soft Tissue Sarcoma - Pipeline Review, H1 2015 - New Market ReportRead the original story w/Photo

    Wednesday | PR-inside.com

    ... Merck & Co., Inc., Merrimack Pharmaceuticals, Inc., Mirati Therapeutics Inc., MolMed S.p.A., Morphotek, Inc., Nanobiotix, Neotropix, Inc., Novartis AG, Oncos Therapeutics Ltd., Onxeo SA, Pfizer Inc., Pharma Mar, S.A., Plexxikon Inc., Polaris ...

    Comment?

  2. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Thursday Aug 27 | Business Wire

    The company is committed to offering healthy and natura... )--Canon U.S.A., a leader in digital imaging solutions, today announced that Graphistudio, an Italian-based wedding photography printer with a name long associated wit... )--The Board of Directors of Myriant Corporation , an affiliate of PTT Global Chemical Public Company Limited , today announced that Cenan Ozmeral, ... )--Regulatory News: NANOBIOTIX , sociA tA franA aise pionniA re en nanomA decine dA veloppant NanoXray, une approche thA rapeutique... )--Regulatory News: NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatmen... )--Arizona Center for Civic Leadership, a program of the Flinn Foundation of Phoenix, announces its 2015 Flinn-Brown Academy Fellows.

    Comment?

  3. New Report Available: PharmaEngine, Inc. (4162) - Financial and Strategic SWOT Analysis ReviewRead the original story

    Jul 28, 2015 | PR-inside.com

    ... the treatment of metastatic pancreatic cancer. The company is partnered with Merrimack Pharmaceuticals, Inc., and Nanobiotix S.A. It has research and development facility. The company has collaboration with Guangzhou BeBetter Medicine Technology ...

    Comment?

  4. Soft Tissue Sarcoma Therapeutic Assessment Pipeline Review H1 2015Read the original story

    Jul 22, 2015 | Emailwire.com

    ... Merck & Co., Inc., Merrimack Pharmaceuticals, Inc., Mirati Therapeutics Inc., MolMed S.p.A., Morphotek, Inc., Nanobiotix, Neotropix, Inc., Novartis AG, Oncos Therapeutics Ltd., Onxeo SA, Pfizer Inc., Pharma Mar, S.A., Plexxikon Inc., Polaris ...

    Comment?

  5. Nanobiotix Revenue For Q2 2015Read the original story

    Jul 14, 2015 | BioSpace

    Paris, France, July 15, 2015 - NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the second quarter of 2015. Income statement Activity NANOBIOTIX's revenue during the second quarter of 2015 corresponds to the upfront payment received by the company from Taiwan-based PharmaEngine, within the framework of the licensing contract signed in August 2012 for the development and commercialization of the lead product, NBTXR3 in the Asia-Pacific region.

    Comment?

  6. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Jul 8, 2015 | Business Wire

    ... ETF DEALING DATE 07-Jul-15 NAV PER SHARE USD45.6305 NUMBER OF SHARES IN ISSUE 46,288,979 CODE )--Regulatory News: Nanobiotix (Paris:NANO): Place de cotation : Euronext Paris de Nyse Euronext Compartiment : Compartiment B Code ISIN : FR0011341205 ...

    Comment?

  7. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Jul 2, 2015 | Business Wire

    ... MTN ISSUE NAME. Our Ref. MJ3275 ISIN Code. XS1241577060 INTEREST AMT PER DENOM. CURRENCY ... )--Regulatory News: Nanobiotix (Paris:NANO): Au titre du contrat de liquidite confie par la societe NANOBIOTIX a la Societe de Bourse Gilbert Dupont, a la ...

    Comment?

  8. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Jul 2, 2015 | Business Wire

    ... MTN ISSUE NAME. Our Ref. MJ3275 ISIN Code. XS1241577060 INTEREST AMT PER DENOM. CURRENCY ... )--Regulatory News: Nanobiotix (Paris:NANO): Au titre du contrat de liquidite confie par la societe NANOBIOTIX a la Societe de Bourse Gilbert Dupont, a la ...

    Comment?

  9. The Drums Of BIO 2015: Dollars, Nano and DataRead the original story w/Photo

    Jul 2, 2015 | Pharmaceutical Online

    ... formulated with surfactants that mediate non-covalent binding of antibodies and other biological molecules. Nanobiotix's product in phase three NBTXR3 is another application of nano that could dramatically help patients. The product consists of ...

    Comment?

  10. NANOBIOTIX: starts Phase I/II clinical trial in liver Metastasis and...Read the original story w/Photo

    Jul 1, 2015 | GlobeNewswire

    NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has been authorized to begin a new clinical trial in liver cancers for its lead NanoXray product, NBTXR3. Clinical trial authorization given by French regulatory body in two cancer patient populations with high global incidence Significant enlargement of potential use of NBTXR3 targeting the fourth and fifth indications after Soft Tissue Sarcoma, Head and Neck cancer and Rectum cancer The French National Agency for Medicines and Health Products gave Nanobiotix the green light to start a Phase I/II trial in two new cancer populations - hepatocellular cancer and liver metastases - for its lead product, NBTXR3.

    Comment?

  11. NANOBIOTIX :reports positive preliminary results in Head and Neck...Read the original story w/Photo

    Jun 10, 2015 | GlobeNewswire

    NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive preliminary safety results for its lead NanoXray product NBTXR3, in its head and neck cancer Phase I/II clinical trial. Intermediate results show the feasibility of the injection of NBTXR3 and a good safety profile of the product for this indication A significant proportion of Head and Neck carcinomas in the western world are found in the oral cavity.

    Comment?

  12. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Jun 9, 2015 | Business Wire

    ... nation's largest independent providers of compression services, has received the EY Entrep... )--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches ...

    Comment?

  13. Nanobiotix reports positive preliminary results in Head and Neck...Read the original story

    Jun 9, 2015 | Business Wire

    Figures: Patient treated with NBTXR3; MRI and CT Scan taken both 24h after injection showing the presence of the product within the tumor NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive preliminary safety results for its lead NanoXray product NBTXR3, in its head and neck cancer Phase I/II clinical trial. Intermediate results show the feasibility of the injection of NBTXR3 and a good safety profile of the product for this indication A significant proportion of Head and Neck carcinomas in the western world are found in the oral cavity.

    Comment?

  14. Novel Drug Delivery Systems in Cancer Therapy Market Size, Share, and Forecasts, 2015 To 2022.Read the original story

    Jun 3, 2015 | PR-inside.com

    ... Merit Medical Systems, Inc., EmboMedics Inc., Eckert & Ziegler BEBIG, Kobo Products, Inc., Polysciences Inc., Nanobiotix, Mo-Sci Corporation and Sirtex Medical Limited. About Grand View Research Grand View Research, Inc. is a U.S. based market ...

    Comment?

  15. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    May 11, 2015 | Business Wire

    Data: Luned... )--SIG Combibloc Group Holdings S.a r.l. kundigt ihre vierteljahrliche Telefonkonferenz zur Erlauterung der Ergebnisse fur das erste Quartal 2015 an. Datum: Montag, 18. Mai... )--Regulatory News: Nanobiotix : Place de cotation : Euronext Paris de Nyse EuronextCompartiment : Compartiment BCode ISIN : FR0011341205Site web : www.nanobiotix.c... )--Nat Geo WILD is making dreams come true with #BarkBreak, an on-call dog service that will personally deliver an adoptable shelter dog for a 30-minute puppy love session.

    Comment?

  16. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    May 11, 2015 | Business Wire

    ... zur Erlauterung der Ergebnisse fur das erste Quartal 2015 an. Datum: Montag, 18. Mai... )--Regulatory News: Nanobiotix (Paris:NANO): Place de cotation : Euronext Paris de Nyse EuronextCompartiment : Compartiment BCode ISIN : FR0011341205Site web : ...

    Comment?

  17. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Apr 29, 2015 | Business Wire

    ... Zhdanovich - Assistant to the President (IR) Thursday, April 30th, 2015 16.00 Moscow / 14.... )--Regulatory News: Nanobiotix (Paris:NANO): Place de cotation : Euronext Paris de Nyse EuronextCompartiment : Compartiment BCode ISIN : FR0011341205Site ...

    Comment?

  18. Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market Trends...Read the original story

    Apr 20, 2015 | PR-inside.com

    ... Merit Medical Systems, Inc., EmboMedics Inc., Eckert & Ziegler BEBIG, Kobo Products, Inc., Polysciences Inc., Nanobiotix, Mo-Sci Corporation and Sirtex Medical Limited. Request TOC of "Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market ...

    Comment?

  19. Global Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market...Read the original story w/Photo

    Apr 20, 2015 | PR-inside.com

    ... Merit Medical Systems, Inc., EmboMedics Inc., Eckert & Ziegler BEBIG, Kobo Products, Inc., Polysciences Inc., Nanobiotix, Mo-Sci Corporation and Sirtex Medical Limited. About Grand View Research Grand View Research, Inc. is a market research and ...

    Comment?

  20. Nanobiotix : 2014 Annual ResultsRead the original story w/Photo

    Apr 14, 2015 | GlobeNewswire

    PARIS, April 14, 2015 -- NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today its audited consolidated results for the fiscal year ended December 31, 2014: Revenue increased mainly as a result of a milestone payment received from PharmaEngine to develop the Soft Tissue Sarcoma indication in the Asia-Pacific region; Expenses were impacted by Nanobiotix's R&D expansion, which has taken lead product NBTXR3 into pivotal phase II/III trials in Soft Tissue Sarcoma and pilot studies in Head and Neck cancer. Philippe MAUBERNA, Chief Financial Officer of Nanobiotix commented: " This has been an important year for Nanobiotix.

    Comment?